BCHT Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 1,252

Employees

  • Stock Symbol
  • 688276

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $2.32
  • (As of Friday Closing)

BCHT General Information

Description

Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.

Contact Information

Website
www.bchtpharm.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 1260 Huoju Road
  • Changchun High-tech Zone
  • Changchun, Jilin
  • China
+86 0431
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • 1260 Huoju Road
  • Changchun High-tech Zone
  • Changchun, Jilin
  • China
+86 0431

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BCHT Stock Performance

As of 13-Nov-2026, BCHT’s stock price is $2.32. Its current market cap is $958M with 414M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.32 $2.40 $1.96 - $3.44 $958M 414M 3.99M -$0.07

BCHT Financials Summary

As of 30-Sep-2026, BCHT has a trailing 12-month revenue of $101M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,135,639 1,134,854 1,393,356 3,118,356
Revenue 100,754 84,139 171,290 257,911
EBITDA (34,945) (27,827) 49,735 91,027
Net Income (29,010) (36,514) 32,345 70,815
Total Assets 768,180 724,402 712,986 711,881
Total Debt 76,570 37,909 14,086 2,888
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BCHT Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BCHT‘s full profile, request access.

Request a free trial

BCHT Patents

  • 39

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

BCHT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4825373-A1 Vaccine lyoprotectant without animal-derived protein component and use thereof Pending 15-Dec-2023
WO-2025123842-A1 Vaccine lyoprotectant without animal-derived protein component and use thereof Inactive 15-Dec-2023
EP-4813406-A1 Mrna vaccine and use thereof Pending 22-Nov-2023
WO-2025107842-A1 Mrna vaccine and use thereof Inactive 22-Nov-2023
EP-4588936-A1 Antibodies specifically binding to rsv Pending 08-Dec-2022 A61P11/00
To view BCHT’s complete patent history, request access »

BCHT Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BCHT Investments & Acquisitions (6)

BCHT’s most recent deal was a Early Stage VC with ChuanXin Biomedicine for . The deal was made on 23-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ChuanXin Biomedicine 23-Jan-2025 Early Stage VC Drug Discovery
ChuanXin Biomedicine 28-Jun-2023 Early Stage VC Drug Discovery
Transcend Biomedical Suzhou 28-Jun-2023 Corporate Biotechnology
Reinovax Biologics 12-Feb-2018 Merger/Acquisition Drug Discovery
Mucosis 16-Jan-2015 Later Stage VC Biotechnology
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

BCHT ESG

Risk Overview

Risk Rating

Updated March, 31, 2025

33.85 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view BCHT’s complete esg history, request access »

BCHT Exits (2)

BCHT’s most recent exit was on 16-Jan-2015 from Mucosis. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Mucosis 16-Jan-2015 Completed
  • 5 buyers
Mucosis 29-Apr-2014 Later Stage VC Completed
  • 5 buyers
To view BCHT’s complete exits history, request access »

BCHT FAQs

  • When was BCHT founded?

    BCHT was founded in 2004.

  • Where is BCHT headquartered?

    BCHT is headquartered in Changchun, China.

  • What is the size of BCHT?

    BCHT has 1,252 total employees.

  • What industry is BCHT in?

    BCHT’s primary industry is Pharmaceuticals.

  • Is BCHT a private or public company?

    BCHT is a Public company.

  • What is BCHT’s stock symbol?

    The ticker symbol for BCHT is 688276.

  • What is the current stock price of BCHT?

    As of 13-Nov-2026 the stock price of BCHT is $2.32.

  • What is the current market cap of BCHT?

    The current market capitalization of BCHT is $958M.

  • What is BCHT’s current revenue?

    The trailing twelve month revenue for BCHT is $101M.

  • What is BCHT’s annual earnings per share (EPS)?

    BCHT’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process